BR112015023343A2 - método para preparar sovaprevir, método de preparar um composto da fórmula (c), método de preparação do composto f-2, composto, processo, método de preparação de uma forma amorfa pura de sovaprevir, e,forma cristalina de sovaprevir - Google Patents
método para preparar sovaprevir, método de preparar um composto da fórmula (c), método de preparação do composto f-2, composto, processo, método de preparação de uma forma amorfa pura de sovaprevir, e,forma cristalina de sovaprevirInfo
- Publication number
- BR112015023343A2 BR112015023343A2 BR112015023343A BR112015023343A BR112015023343A2 BR 112015023343 A2 BR112015023343 A2 BR 112015023343A2 BR 112015023343 A BR112015023343 A BR 112015023343A BR 112015023343 A BR112015023343 A BR 112015023343A BR 112015023343 A2 BR112015023343 A2 BR 112015023343A2
- Authority
- BR
- Brazil
- Prior art keywords
- preparing
- sovaprevir
- compound
- crystalline form
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Abstract
resumo método para preparar sovaprevir, método de preparar um composto da fórmula (c), método de preparação do composto f-2, composto, processo, método de preparação de uma forma amorfa pura de sovaprevir, e,forma cristalina de sovaprevir a divulgação inclui novos processos para a produção de sovaprevir compreendendo a adição do composto e a f-1 para fornecer sovaprevir. a divulgação inclui ainda intermediários úteis para a produção de sovaprevir. a divulgação também inclui uma nova forma cristalina de sovaprevir, forma f, e um método para a preparação de sovaprevir amorfo seco por pulverização a partir da forma cristalina f. 1/1
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361784182P | 2013-03-14 | 2013-03-14 | |
PCT/US2014/028278 WO2014152928A2 (en) | 2013-03-14 | 2014-03-14 | Novel processes for producing sovaprevir |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112015023343A2 true BR112015023343A2 (pt) | 2017-07-18 |
Family
ID=50680160
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112015023343A BR112015023343A2 (pt) | 2013-03-14 | 2014-03-14 | método para preparar sovaprevir, método de preparar um composto da fórmula (c), método de preparação do composto f-2, composto, processo, método de preparação de uma forma amorfa pura de sovaprevir, e,forma cristalina de sovaprevir |
Country Status (13)
Country | Link |
---|---|
US (2) | US9115175B2 (pt) |
EP (1) | EP2970195B1 (pt) |
JP (1) | JP2016515139A (pt) |
KR (1) | KR20160005334A (pt) |
CN (1) | CN105408317A (pt) |
AU (1) | AU2014236502A1 (pt) |
BR (1) | BR112015023343A2 (pt) |
CA (1) | CA2905433A1 (pt) |
EA (1) | EA201591722A1 (pt) |
IL (1) | IL241287A0 (pt) |
PH (1) | PH12015502121A1 (pt) |
SG (1) | SG11201507469RA (pt) |
WO (1) | WO2014152928A2 (pt) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008008502A1 (en) | 2006-07-13 | 2008-01-17 | Achillion Pharmaceuticals, Inc. | 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication |
WO2017197046A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | C3-carbon linked glutarimide degronimers for target protein degradation |
CN109562113A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的螺环降解决定子体 |
WO2017197055A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6323180B1 (en) | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
US6608027B1 (en) | 1999-04-06 | 2003-08-19 | Boehringer Ingelheim (Canada) Ltd | Macrocyclic peptides active against the hepatitis C virus |
BR0115447A (pt) | 2000-11-20 | 2005-10-18 | Bristol Myers Squibb Co | Inibidores de tripeptìdeo de hepatite c |
US20060199773A1 (en) | 2002-05-20 | 2006-09-07 | Sausker Justin B | Crystalline forms of (1R,2S)-N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(6-methoxy-1-isoquinolinyl)oxy]-L-prolyl-1-amino-N-(cyclopropylsulfonyl)-2-ethenyl-cyclopropanecarboxamide, monopotassium salt |
ATE481106T1 (de) | 2002-05-20 | 2010-10-15 | Bristol Myers Squibb Co | Heterocyclische sulfonamid-hepatitis-c-virus- hemmer |
MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
AU2003301959A1 (en) | 2002-05-20 | 2004-06-03 | Bristol-Myers Squibb Company | Substituted cycloalkyl p1' hepatitis c virus inhibitors |
ATE503764T1 (de) | 2002-05-20 | 2011-04-15 | Bristol Myers Squibb Co | Inhibitoren des hepatitis-c-virus |
CN1771050A (zh) | 2003-02-07 | 2006-05-10 | 益安药业 | 丙型肝炎丝氨酸蛋白酶的大环抑制剂 |
DE602004029866D1 (de) | 2003-03-05 | 2010-12-16 | Boehringer Ingelheim Pharma | Peptidanaloga mit inhibitorischer wirkung auf hepatitis c |
WO2004094452A2 (en) | 2003-04-16 | 2004-11-04 | Bristol-Myers Squibb Company | Macrocyclic isoquinoline peptide inhibitors of hepatitis c virus |
US7176208B2 (en) | 2003-04-18 | 2007-02-13 | Enanta Pharmaceuticals, Inc. | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors |
CN1791599A (zh) | 2003-05-21 | 2006-06-21 | 贝林格尔.英格海姆国际有限公司 | 丙型肝炎抑制剂化合物 |
WO2004113365A2 (en) | 2003-06-05 | 2004-12-29 | Enanta Pharmaceuticals, Inc. | Hepatitis c serine protease tri-peptide inhibitors |
UY28423A1 (es) | 2003-07-18 | 2005-02-28 | Vertex Pharma | Inhibidores de proteasas serinas, en especial proteasa ns3-ns4a del vhc.- |
CA2536182C (en) | 2003-09-22 | 2012-07-24 | Boehringer Ingelheim International Gmbh | Macrocyclic peptides active against the hepatitis c virus |
RS20060259A (en) | 2003-10-14 | 2008-08-07 | Intermune Inc., | Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of hcv replication |
US7132504B2 (en) | 2003-11-12 | 2006-11-07 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7135462B2 (en) | 2003-11-20 | 2006-11-14 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7309708B2 (en) | 2003-11-20 | 2007-12-18 | Birstol-Myers Squibb Company | Hepatitis C virus inhibitors |
ES2358333T3 (es) | 2004-01-21 | 2011-05-09 | Boehringer Ingelheim International Gmbh | Péptidos macrocíclicos con acción contra el virus de la hepatitis c. |
AR048401A1 (es) | 2004-01-30 | 2006-04-26 | Medivir Ab | Inhibidores de la serina-proteasa ns3 del vhc |
JP4654239B2 (ja) | 2004-03-15 | 2011-03-16 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | C型肝炎ウィルス感染症の治療に適した大環状ジペプチドの調製方法 |
EA012389B1 (ru) | 2004-03-30 | 2009-10-30 | Интермун, Инк. | Макроциклические соединения в качестве ингибиторов вирусной репликации |
CA2573346C (en) | 2004-07-20 | 2011-09-20 | Boehringer Ingelheim International Gmbh | Hepatitis c inhibitor peptide analogs |
UY29016A1 (es) | 2004-07-20 | 2006-02-24 | Boehringer Ingelheim Int | Analogos de dipeptidos inhibidores de la hepatitis c |
WO2006033878A1 (en) | 2004-09-17 | 2006-03-30 | Boehringer Ingelheim International, Gmbh | Process for preparing macrocyclic hcv protease inhibitors |
US7323447B2 (en) | 2005-02-08 | 2008-01-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
WO2006096652A2 (en) | 2005-03-08 | 2006-09-14 | Boehringer Ingelheim International Gmbh | Process for preparing macrocyclic compounds |
US7592336B2 (en) * | 2005-05-10 | 2009-09-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7608592B2 (en) | 2005-06-30 | 2009-10-27 | Virobay, Inc. | HCV inhibitors |
US7601686B2 (en) | 2005-07-11 | 2009-10-13 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
TWI389908B (zh) | 2005-07-14 | 2013-03-21 | Gilead Sciences Inc | 抗病毒化合物類 |
EP1910378B1 (en) | 2005-07-20 | 2012-06-20 | Boehringer Ingelheim International GmbH | Hepatitis c inhibitor peptide analogs |
EP2305695A3 (en) | 2005-07-25 | 2011-07-27 | Intermune, Inc. | Macrocyclic inhibitors of Hepatitis C virus replication |
JO2768B1 (en) | 2005-07-29 | 2014-03-15 | تيبوتيك فارماسيوتيكالز ليمتد | Large cyclic inhibitors of hepatitis C virus |
ES2364426T3 (es) | 2005-09-09 | 2011-09-02 | Boehringer Ingelheim International Gmbh | Proceso de metátesis con cerrado del anillo para la preparación de péptidos macrocíclicos. |
BRPI0617274A2 (pt) | 2005-10-11 | 2011-07-19 | Intermune Inc | compostos e métodos para a inibição de replicação viral de hepatite c |
US7772183B2 (en) | 2005-10-12 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7741281B2 (en) | 2005-11-03 | 2010-06-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
SI2041156T1 (sl) * | 2006-07-13 | 2014-04-30 | Achillion Pharmacetuticals, Inc. | Peptidi 4-amino-4-oksobutanoila kot inhibitorji virusne replikacije |
WO2008008502A1 (en) | 2006-07-13 | 2008-01-17 | Achillion Pharmaceuticals, Inc. | 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication |
PT2364309E (pt) | 2008-12-10 | 2015-01-14 | Achillion Pharmaceuticals Inc | Novos péptidos 4-amino-4-oxobutanoil como inibidores de replicação viral |
-
2014
- 2014-03-14 CA CA2905433A patent/CA2905433A1/en not_active Abandoned
- 2014-03-14 JP JP2016502751A patent/JP2016515139A/ja active Pending
- 2014-03-14 AU AU2014236502A patent/AU2014236502A1/en not_active Abandoned
- 2014-03-14 EA EA201591722A patent/EA201591722A1/ru unknown
- 2014-03-14 US US14/211,510 patent/US9115175B2/en not_active Expired - Fee Related
- 2014-03-14 BR BR112015023343A patent/BR112015023343A2/pt not_active IP Right Cessation
- 2014-03-14 WO PCT/US2014/028278 patent/WO2014152928A2/en active Application Filing
- 2014-03-14 EP EP14722457.0A patent/EP2970195B1/en not_active Not-in-force
- 2014-03-14 CN CN201480028569.7A patent/CN105408317A/zh active Pending
- 2014-03-14 SG SG11201507469RA patent/SG11201507469RA/en unknown
- 2014-03-14 KR KR1020157028998A patent/KR20160005334A/ko not_active Application Discontinuation
-
2015
- 2015-07-20 US US14/803,234 patent/US9481708B2/en not_active Expired - Fee Related
- 2015-09-07 IL IL241287A patent/IL241287A0/en unknown
- 2015-09-14 PH PH12015502121A patent/PH12015502121A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
SG11201507469RA (en) | 2015-10-29 |
CN105408317A (zh) | 2016-03-16 |
EA201591722A1 (ru) | 2016-02-29 |
US9481708B2 (en) | 2016-11-01 |
CA2905433A1 (en) | 2014-09-25 |
AU2014236502A1 (en) | 2015-10-01 |
EP2970195B1 (en) | 2017-08-02 |
WO2014152928A3 (en) | 2015-01-08 |
PH12015502121A1 (en) | 2016-01-25 |
JP2016515139A (ja) | 2016-05-26 |
US20150322109A1 (en) | 2015-11-12 |
EP2970195A2 (en) | 2016-01-20 |
US9115175B2 (en) | 2015-08-25 |
KR20160005334A (ko) | 2016-01-14 |
US20140275480A1 (en) | 2014-09-18 |
IL241287A0 (en) | 2015-11-30 |
WO2014152928A2 (en) | 2014-09-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DOP2021000179A (es) | Procedimiento de preparación de 5-fluoro-1h-pirazolopiridinas sustituidas | |
SA518400053B1 (ar) | عملية مُحسنة لإنتاج حمض أكريليك | |
BR112012011689A2 (pt) | processo para a produção de etexilato de dabigatran | |
BR112015029933B8 (pt) | Método de produção de tagatose | |
BR112013001245A2 (pt) | método de produção de ingenol-3-angelato | |
BR112014024493A2 (pt) | método para a produção enzimática de isoprenol usando mevalonato como substrato | |
BR112012011961A2 (pt) | processo para produzir cloretos de ácido 5-flúor-1-alquil-3-fluoralquil-1h-pirazol-4-carboxílico | |
CL2011000296A1 (es) | Proceso de preparación del ester metílico del ácido 4-oxo-octahidro-indol-1-carboxílico y compuestos intermediarios utilizados. | |
AR095297A1 (es) | Método para preparar un compuesto de piripiropeno | |
BR112015029399A2 (pt) | produção em etapa única de uma composição de polipropileno | |
BR112015023343A2 (pt) | método para preparar sovaprevir, método de preparar um composto da fórmula (c), método de preparação do composto f-2, composto, processo, método de preparação de uma forma amorfa pura de sovaprevir, e,forma cristalina de sovaprevir | |
BR112017011275A2 (pt) | composição, e, processo para a produção de xarope de glicose. | |
AR085291A1 (es) | Metodos para sintetizar derivados del precursor z de molibdopterina | |
BR112015024859A2 (pt) | processo e intermediários para a preparação de pregabalina | |
EP2770089A4 (en) | METHOD FOR PRODUCING A NITRIDE SEMICONDUCTOR CRYSTAL OF A GROUP 13 METAL OF THE PERIODIC TABLE AND A NITRIDE SEMI-CONDUCTIVE CRYSTAL OF A GROUP 13 METAL OF THE PERIODIC TABLE PRODUCED BY SAID PRODUCTION PROCESS | |
MX2016007340A (es) | Formulacion de biomasa. | |
BR112015014440A2 (pt) | processo para a produção de uma solução aquosa purificada de peróxido de hidrogênio | |
BR112014018492A8 (pt) | Processo aperfeiçoado para a produção de etileno 1,1-disubstituído | |
WO2015090500A3 (en) | Method for the production of single crystalline mgtio3 flakes | |
BR112015028751A2 (pt) | processo para a preparação de derivados de 3,5-bis (fluoralquil)pirazol a partir de alfa,alfa-dihaloaminas | |
BR112012002749A2 (pt) | processo para a produção de módulos solares | |
TN2015000336A1 (en) | Production method of pyridazinone compounds | |
MX364769B (es) | Proceso para producir 2-fenil-1, 3-benzoxazoles. | |
BR112015017326A2 (pt) | processo para a produção de 2-alquil-3-butin-2-óis | |
FR3041658B1 (fr) | Procede de production de l-methionine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |